Terminal · Institutions

Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.

Opus Point Partners Management, LLC 13F Holdings -- Portfolio & Top Positions (2019-09-30)

Opus Point Partners Management, LLC (CIK 1600175) reported $55.3M across 53 reported positions in its SEC 13F filing for 2019-09-30. Largest positions: IBB ($20.9M, 37.76%), LABU ($3.1M, 5.58%), MTD ($2.3M, 4.12%), BMY ($1.7M, 3.02%), SGEN ($1.5M, 2.78%). Source: SEC Form 13F.

RankTickerCompanyValue% PortfolioSharesAction
1IBBISHARES TR$20.9M37.76%210,000Hold
2LABUDIREXION SHS ETF TR$3.1M5.58%99,855Added
3MTDMETTLER TOLEDO INTERNATIONAL$2.3M4.12%3,235Hold
4BMYBRISTOL MYERS SQUIBB CO$1.7M3.02%33,000Hold
5SGENSEATTLE GENETICS INC$1.5M2.78%18,020Added
6ILMNILLUMINA INC$1.4M2.59%4,721Added
7VRTXVERTEX PHARMACEUTICALS INC$1.4M2.54%8,279Added
8IONSIONIS PHARMACEUTICALS INC$1.2M2.18%20,124Hold
9ALNYALNYLAM PHARMACEUTICALS INC$1.1M1.99%13,684Added
10ALXNALEXION PHARMACEUTICALS INC$973,0001.76%9,933Added
11QGENQIAGEN NV$951,0001.72%28,858Hold
12ONCESPARK THERAPEUTICS INC$941,0001.70%9,699Hold
13FBIOFORTRESS BIOTECH INC$865,0001.56%613,551Added
14PRQRPROQR THRAPEUTICS N V$798,0001.44%138,461Hold
15INCYINCYTE CORP$791,0001.43%10,659Added
16EXASEXACT SCIENCES CORP$771,0001.39%8,534Hold
17REGNREGENERON PHARMACEUTICALS$677,0001.22%2,439Added
18BMRNBIOMARIN PHARMACEUTICAL INC$654,0001.18%9,700Added
19DCPHDECIPHERA PHARMACEUTICALS IN$632,0001.14%18,631Hold
20ASNDASCENDIS PHARMA A S$596,0001.08%6,190Hold
21CELGCELGENE CORP$559,0001.01%5,625Hold
22QUREUNIQURE NV$560,0001.01%14,215Hold
23CRSPCRISPR THERAPEUTICS AG$542,0000.98%13,214Hold
24EPZMEPIZYME INC$520,0000.94%50,378Hold
25AMRNAMARIN CORP PLC$510,0000.92%33,641Added

Source: SEC Form 13F filings · as of 2019-09-30